Onyx Pharmaceuticals Said to Weigh Sale
Onyx Pharmaceuticals Inc. (ONXX), the developer of the kidney-cancer treatment Nexavar, is exploring strategic options, including a possible sale, said two people with knowledge of the matter.Potential buyers are studying Onyx’s business and its carfilzomib cancer therapy, said one of the people who declined to be identified as the discussions are private. Onyx, based in South San Francisco, had a market value of about $2.4 billion as of Nov. 25 and is working with Centerview Partners LLP to review alternatives, said the people.
Lori Melancon, a spokeswoman for Onyx, declined to comment, as did a spokeswoman for Centerview. No deal is certain and the business review is still at a preliminary stage, the people said.
Here is full story- Right Here
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/
